WO2000008092A1 - Controlled release polyacrylic acid granules and a process for preparing the same - Google Patents

Controlled release polyacrylic acid granules and a process for preparing the same Download PDF

Info

Publication number
WO2000008092A1
WO2000008092A1 PCT/US1999/016227 US9916227W WO0008092A1 WO 2000008092 A1 WO2000008092 A1 WO 2000008092A1 US 9916227 W US9916227 W US 9916227W WO 0008092 A1 WO0008092 A1 WO 0008092A1
Authority
WO
WIPO (PCT)
Prior art keywords
polyacrylic acid
granules
acid
water
tablet
Prior art date
Application number
PCT/US1999/016227
Other languages
French (fr)
Inventor
Daniel James Adams
David William Weaver
Original Assignee
The B.F. Goodrich Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The B.F. Goodrich Company filed Critical The B.F. Goodrich Company
Priority to EP99934124A priority Critical patent/EP1183302B1/en
Priority to JP2000563720A priority patent/JP4371394B2/en
Priority to DE69929439T priority patent/DE69929439T2/en
Priority to BRPI9912846-2A priority patent/BR9912846B1/en
Priority to MXPA01000894A priority patent/MXPA01000894A/en
Priority to AU50024/99A priority patent/AU5002499A/en
Publication of WO2000008092A1 publication Critical patent/WO2000008092A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/12Powdering or granulating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29BPREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00Making granules
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29BPREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00Making granules
    • B29B9/08Making granules by agglomerating smaller particles
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29BPREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00Making granules
    • B29B9/12Making granules characterised by structure or composition
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29BPREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00Making granules
    • B29B9/16Auxiliary treatment of granules
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/12Powdering or granulating
    • C08J3/16Powdering or granulating by coagulating dispersions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2033/00Use of polymers of unsaturated acids or derivatives thereof as moulding material
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2333/00Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
    • C08J2333/02Homopolymers or copolymers of acids; Metal or ammonium salts thereof

Definitions

  • the present invention concerns a process for producing granulated polyacrylic acid.
  • the polyacrylic polymers are highly swollen in aqueous media.
  • the polyacrylic acid granules produced by the proc ⁇ ess of the present invention are useful in controlled release formulations (such as pharmaceutical tablets) .
  • the powdered form of polyacrylic acid which was previously used in controlled release applications, cre- ated material handling problems due to its poor powder flow character ⁇ istics, dust, and static charges associated with the dust.
  • Polyacrylic acid resins which are to be used in applications involving swelling with aqueous electrolyte solutions, are commonly polymerized in nonaqueous polymerizations where the insoluble polymer can be isolated as powders. These powders, comprised of aggregated or agglomerated polymer chains, are significantly easier to disperse and dissolve in water than the bulk polymer. However these polyacrylic acid powders have been noted for their static electricity charge, poor powder flow and some difficult in making dispersions in water since their introduction in 1 958.
  • Hot roll milling uses heat along with pressure to squeeze the powder into flakes or sheets. In either case, the compacted material is then reground into particles larger than the original powder grains. Both slugging and roll milling are relatively slow, low-capacity, energy- intensive processes. Roll milling has the additional disadvantages of re- quiring constant attention by a skilled operator.
  • Dry agglomeration techniques involve adding liquid to the original powder to increase the particle sizes and then drying the larger particles in trays or a fluidized bed. The resulting agglomerates can be used as is or ground to smaller sizes for specific uses. Dry granulation eliminates several problems inherent in conventional processes. Dry granulation of powder material is a two-step process, requiring no heating or wetting (depending on the starting ma ⁇ terial), in which the powder is first densified (compacted) into solid form, then broken into smaller particles and separated into predeter- mined sizes. To perform these steps, a granulation system combines several different kinds of specialized machines (usually in a vertical, gravity- assisted arrangement) to achieve a closed-loop operation. System components typically include: a feeding hopper, horizontal and vertical screws, compaction rollers, a prebreaker, a granulator, sizing/sorting screens, and a recycling elevator.
  • Granulated particles formed by the above processes are more easily handled than the powder from which they are formed.
  • the granular particles may be too hard, too soft, too friable or not par- ticularly suitable, due to the particle size distribution, for their end use
  • the present invention pertains to a method for forming polyacrylic acid granules and granules formed therefrom wherein the granules are flowable, have comparable swelling characteristics and provide comparable tablet properties to powdered polyacrylic acid, have increased bulk density, and contain minimal amounts of very small par ⁇ ticles that can cause dusting and/or static adherence.
  • the granules from this process vary from other granules of similar materials in that they retain more of their dissolution and swelling characteristics in both aqueous solutions in slow release tablets than do prior art polyacrylic acid granules.
  • the granules formed by the method of the present in ⁇ vention can be used to prepare controlled release tablets, especially controlled release pharmaceutical tablets where the granules have surprisingly similar characteristics during tablet formation with powders and form tablets with similar controlled release rates to tablets from the harder to handle powders. They can also be used as thickeners; emulsi- fiers and suspending agents in water based formulations based on other polar solvents.
  • a first advantage of the present invention is that polyacrylic acid powder is formulated into a granular product with better dry flow characteristics facilitating metering and mixing operations.
  • An additional advantage is the production of a granular polyacrylic acid having better control over particle size, higher bulk density to minimize packaging, and lower static adherence compared to unprocessed powdered polyacrylic acid.
  • a further advantage is that the granular polyacrylic acid produced in accordance with the present invention has relatively low dusting compared to the powder form of polyacrylic acid.
  • a still further advantage of the granular polyacrylic acid of the present invention is that it results in the unexpectedly better controlled release of various active material from tablets formed from the granules than from tablets formed from granules produced by other granulation processes.
  • polyacrylic acid is used to include various homo- polymers and copolymers wherein at least 50 or 75 mole percent of the repeating units have pendant carboxylic acid groups or anhydrides of di- carboxylic acid groups. While acrylic acid is the most common primary monomer used to form polyacrylic acid the term is not limited thereto but includes generally all ⁇ - ⁇ unsaturated monomers with carboxylic pendant groups or anhydrides of dicarboxylic acids as described in U.S. 5,349,030. Other advantages and benefits of the invention will be ⁇ come apparent to those skilled in the art upon a reading and under- standing of the following detailed description of the preferred embodiments.
  • a dry granulation apparatus A is provided as shown in the Figure.
  • Variables such as the compaction pressure, roll speeds, attrition device and operation speed, and screening operations are used to control the particle densification and particle size distribution. These properties control the dissolution behavior of the polyacrylic acid when exposed to water or electrolyte solutions and its effectiveness as an additive in tablet formulations and controlled release applications.
  • the dry granulator A is provided with an original powder feed 1 0 which feeds powdered polyacrylic acid into a lower hopper 1 2.
  • the powdered acrylic acid in lower hop- per 1 2 is then fed through feed channel 1 4 into an upper hopper 1 6.
  • the upper hopper 1 6 collects the virgin powdered polyacrylic acid and recycled powder which does not meet quality controlled sizing pa ⁇ rameters.
  • the powdered acrylic acid in the upper hopper is then ini ⁇ tially fed into the granulation system via a horizontal feed screw 1 8.
  • the rate of rotation of the horizontal feed screw 1 8 can be adjusted to permit continuous flow of the powdered polyacrylic acid into the granulation system without clogging.
  • a vertical screw 20 pre- compresses and deaerates the powered polyacrylic acid before feeding it into compaction rollers 22. Pressure is applied to compaction rollers 22 via a hydraulic actuator 24.
  • the compaction rollers rotate in oppo ⁇ site directions so that powdered material fed from above will be pulled between the rollers, compressed and dropped into a prebreak mechanism 26 below.
  • the prebreak mechanism 26 provides an initial breakup of the compressed polyacrylic acid into chips and flakes, which drop into attritor 28.
  • the attritor 28 breaks up the compressed polyacrylic acid into desired particle sizes in conjunction with screen
  • Granulated polyacrylic acid falls into a screening system 32 wherein particles are separated via various sieves 34, the final product having the desired particle sizes being deposited into finished product hopper 36.
  • the oversized and undersized particles 38 are processed via a recycle feed mechanism 40 back into feed channel 1 4, 42 to be reprocessed through the system.
  • Various powdered polyacrylic acids, or mixtures of polyacrylic acids may be granulated according to the process of the present invention wherein the resulting granulated polyacrylic acid has en- hanced handling and performance properties compared to the powder.
  • the granulated polyacrylic acid prepared in accordance with the method described herein, when formulated into tablets retains an ability to slow down the release rate of an active material, compared to tablets formed from granules prepared by other known granulation processes.
  • the granules also maintain more of their ability to thicken, emulsify, and suspend in water based formulations and formulations based on other polar solvents than prior art granules.
  • Polymeric powders which may be formed into granules that have improved handling, while retaining thickening and controlled release properties, include various acrylic acid homopolymers, copoly- mers, and interpolymers having a bulk density below about 0.3 g/cc.
  • the term polyacrylic acid or acrylic acid polymers is used to encom ⁇ pass a variety of polymers having high percentages of polymerizable monomers therein with pendant carboxylic acid groups or anhydrides of polycarboxylic acid. These are described in more detail in U.S. Pat ⁇ ents 2,798,053; 3,91 5,921 ; 4,267, 1 03; 5,288,81 4; and 5,349,030 hereby incorporated by reference.
  • polyacrylic acid is used to include various homopolymers, copolymers, and interpolymers, wherein at least 50 or 75 mole percent of the repeating units have pendant carboxylic acid groups or anhydrides of dicarboxylic acid groups. While acrylic acid is the most common primary monomer used to form polyacrylic acid the term is not limited thereto but includes generally all ⁇ - ⁇ unsaturated monomers with carboxylic pendant groups or anhydrides of dicarboxylic acids as described in U.S. 5,349,030. The term consisting essentially of anhydrous polyacrylic acid will be used to exclude more than 3 weight percent water and to exclude more than 0.2 mole percent multivalent metal cations based on the moles of carboxylic acid.
  • the amount of water is less than 1 or 2 weight percent.
  • the amount of multivalent metal cations is less than 0.1 mole percent and preferably less than 0.01 mole percent.
  • the process according to the present inventions is useful for granulating various powdered polycarboxylic acids including cross-linked polyacrylic acids.
  • specific types of cross-linked polyacrylic acids include Carbopol® 971 P (polymerized in ethyl-acetate and partially neutralized with potassium); copolymers of acrylic acid and alkyl acrylates; copolymers of acrylic acid and alkyl vinyl ethers; copolymers of ethylene and maleic anhydride; and copolymers of maleic anhydride and alkyl vinyl ethers.
  • An approved polyacrylic acid for pharmaceutical applications is a polyacrylic acid crosslinked with polyalkenyl ethers.
  • the polymeric agents useable in the present in ⁇ vention are typically polymerized by precipitation polymerization in a non-aqueous medium and subsequently dried to strip off the solvent.
  • the acrylic polymers typically have a flow index of above 30, appar ⁇ ently due to their low bulk density and electrostatic charge.
  • the acrylic polymers of interest when dispersed in water and neutralized to a pH of 7 at a concentration of 1 0 g/L generally can im- part a viscosity of at least 500 centipoise and more desirably at least 2000 centipoise to the water solution as measured by a Brookfield viscometer using 20 rpm at 25 °C and selecting a spindle resulting in a torque reading between 1 0 and 90% of full scale.
  • the improved handling properties of the granules prepared in accordance with the present invention are reflected by improvements over the powdered form of polyacrylic acid in areas such as powder flow rate, bulk density, percentage of fines (i.e. particles less than 325 U.S. Standard screen size), static adherence and total dust.
  • the granulated product desirably retains the at least 70, 80 or 90% of the thickening capacity of the original fine powder when dispersed in water and neutralized to a pH of 7 at a concentration of 1 0 g/L.
  • the viscosity of such a solution is desirably at least 350, 400, or 450 centipoise and more desirably at least 1 400, 1 600 or 1 800 centipoise.
  • the granules according to the present invention may have a flow index value of less than or equal to 25, desirably less than or equal to 20, and preferably less than or equal to 1 5.
  • the flow index is measure by the FlodexTM equipment, which comprises a 35-45 mm diameter tube approximately 8-1 0 cm long. Bottom caps with incrementally larger diameter apertures are used in the apparatus until an aperture is found of sufficient diameter that the contents of the tube are substantially emptied from the tube when the aperture is unblocked by the operator.
  • a flow index value is assigned equal to the diameter of the aperture used in mm through which the material flows easily. If the aperture is too small then bridging over occurs with a substantial amount of the tube contents being retained in the tube.
  • the bulk density of the granules is measured according to a typical bulk density method for powders.
  • a 30-1 00 mL cup is used which can be lightly tapped one time after filling.
  • the powder is dropped from a powder funnel which discharges about 4 to 8 cm above the rim of the cup.
  • the excess material which accumulates above the rim of the cup can be removed by scraping with a spatula and the weight of the contents determined.
  • the bulk density is the weight of the contents divided by their volume.
  • a tap density can also be determined using a 1 00 mL graduated cylinder instead of a cup.
  • the powder is discharged from the bottom of a powder funnel as set forth above.
  • a tap density apparatus such as a J. Engelsmann A-G Tap Density Apparatus is used to tap the cylinder and contents 1 000 times. The volume and weight of the powder after tapping is recorded and the density is calculated as the weight divided by the volume.
  • the amount of granules that pass through said 325 mesh screen are less than 1 0 weight per- cent of the total granules, more desirably less than 5 weight percent, and preferably less than 2 weight percent of the granulated product after screening.
  • the amount of granules passing through a 325 mesh screen can be determined by screening the granules until the weight of the material passing through the 325 mesh screen appears to be constant. If a screen analysis on the polyacrylic powder (before granulation) is desired, small sample sizes or air filtration techniques are recommended due to the substantial amount of very small parti ⁇ cles in the powder and static charge problems that occur during screening. Static charging for polyacrylic acid is generally visually de ⁇ termined. Powder samples in bags will exhibit a strong tendency for dust to adhere to the bag and any equipment and/or the operator. Samples of polyacrylic acid powder in glass and plastic jars (generally nonconductive) will exhibit large amounts of dust adhered by static electricity to the walls of the jar above the samples. Static charged dust particles will appear to exit the glass jar as a smoke due to static repulsion combined with Browman particle diffusion.
  • a number of adjustable parameters must be controlled. These parameters include horizontal feed screw rate of rotation, vertical screw rotation speed, pressure applied to compaction rolls, speed of compaction rolls, attritor configuration and speed, and screen size.
  • the speeds of the horizontal and vertical screws should be set to feed powder to the compaction rollers at a rate just fast enough to cause a slight separation (about 0.01 to about 0.2 or 0.5 inches, more desirably from about 0.02 to about 0.07 or 0.2 inch gap) between the rollers.
  • Pressure is applied to the compaction rollers via the hydraulic actuator or other compaction device to produce a compacted mate ⁇ rial having a density of about 0.3 g/cc to about 1 .5 g/cc.
  • the density of the compacted material is from about 0.9 g/cc to about 1 .1 g/cc.
  • the compaction rolls may have circumferiential corrugations, pocket indentations or corru- gations in the axial direction across the width of the roll .
  • Applicants define the pressure via the result due to the complexity of specifying a compaction pressure applied from a curved surface to a powder.
  • Densification obviously is the result of compacting the aggregates and/or agglomerates (particles) present in the powder into larger particles. This reduces the void volume within the particles. It is believed that the void volume, to the extent that it is open to the surface of the particles, is a pathway for water or electrolyte solutions to enter each particle uniformly swelling the polyacrylic acid therein. Thus densification usually makes the interior of the particles less accessible to water or electrolyte solutions.
  • Increased compaction also results in more interpolymer penetration between the surface polymers on aggregates and/or agglomerates, which can slow dissolution times of a particle due to the need for the interpenetrated polymers to separate and due to the possibility that the interpenetrated polymers may remain entangled and not be able to separate. It is to be noted that if the polyacrylic acid is over-densified then the resulting granules will only swell with water or electrolyte on their surfaces. This results in occlusions of nonswollen polymer (occluded polymer) within some or all granules.
  • the occluded (non-swellable) polyacrylic acid is not available to modify the viscosity of liquid solutions and is not available to control release rates in a tablet. Therefore there is an inverse relationship between the amount of occluded polyacrylic acid and the thickening and release controlling properties of the polyacrylic acid.
  • the compaction roller speed is set to maximize productivity without exceeding the horsepower limitation of the compaction equipment. Slower roller speeds allow the polyacrylic acid more time to flow and accommodate the stresses uniformly throughout the thickness of the compressed samples. Faster roller speeds may force the polyacrylic acid in direct contact with the roller surface to do most of the accommodation.
  • the speed and configuration of the attritor are chosen to provide optimal particle size distributions for a particular application.
  • Smaller particles such as those sized between the opening of a 1 00 and 200 mesh screen are desirable as they maximize the number of particles and total surface area. These properties are important, as smaller polyacrylic acid particles tend to form a tablet with better integrity and slower release rates for active material. Increases in the number of smaller particles decreases bulk density and decrease powder flow characteristics. It has also been observed that smaller particles form tablets with better tablet integrity in the dissolution tests. Larger particles, e.g. those sized between a 20 and 80 mesh screen, maximize bulk density and flow characteristics but contribute less to tablet formation and slow release rates. In most embodiments it is desirable to minimize generation of granules smaller than 325 mesh, more desirable less than 200 mesh (U .S. Standard) due to their con- tribution to dust.
  • Screen size is about 5 mesh to about 325 mesh (U.S. Standard); more desirably from about 20 to about 250, and preferably, screen size is from about 40 mesh to about 200 mesh.
  • granules having a particle size of less than about 5 mesh (passing through 5 mesh) but greater than about 325 mesh (retained on 325 mesh) will be discharged as product.
  • Particles which have sizes outside these parameters (oversized and undersized (fines)) will desirably be recycled back into the system if present in a significant amount.
  • Vacuum deaeration may be used to reduce air from becom- ing trapped in the powder prior to compaction.
  • the vacuum may be adjusted to be from about 0.5 in. Hg. to about 30 in. Hg. Preferably 5 to 20. Desirably this vacuum is applied around the compaction rolls and optionally within the vertical and/or horizontal screw feeds. If al ⁇ ternative compaction or powder conveyance means are used they could include vacuum deaeration. Entrained air in the material from the initial compaction tends to expand uncontrollably as the com- pacted material comes out of the compaction rolls and fracture the compacted material.
  • the controlled release tablet formulations of the present invention include granulated polyacrylic acid prepared in accordance with the process of the invention. Amounts of polyacrylic acid used in tablet formulations are preferably from about 5 or 1 0% w/w to about 50 %w/w.
  • the polyacrylic acid aids in tablet formation and tablet integrity. During controlled release applications the polyacrylic acid can swell which limits the porosity of the tablet (or application device) by restricting the flow of the electrolyte solution into and out of the tablet.
  • the tablets made according to this disclosure have a release rate of from about 0.6 to about 24 hours or more for pharmaceutically active materials. Longer release rates are available for non-pharmaceutical applications where the longer release rates may be desirable.
  • tableting adjuvants including pharma ⁇ ceutically acceptable tableting adjuvants
  • Such adjuvants include fillers, excipients, compression aids, binders, flavorings, coating agents, etc.
  • active materials e.g. pharmaceuticals
  • Other active materials include biocides, disinfectants, stimulants, moisturizers, aromas, scents, chemicals (e.g. chlorine), proteins, etc which are beneficially applied from a table or gelled or thickened liquid formula- tion.
  • pharmaceuticals dosages are designed to be adminis ⁇ tered in specific amounts over a broad time range to avoid toxicity problems, thus the need for controlled release formulations .
  • Pharma ⁇ ceutical can include pain relievers, stimulants, muscle relaxants, anti ⁇ biotics, pain blockers, and a variety of other medications.
  • Theophyl- line for example, is one such agent, which is generally formulated in a controlled release tablet composition.
  • Other pharmaceutical agents typically or desirably used in controlled release form are within the scope of acceptable pharmaceutical agents useable in the present invention's formulations.
  • the following examples utilized a Fitzpatrick Model 4L x 1 0D Chilsonator and DKAS01 2 FitzMill system. This equipment is illustrated in Figure 1 .
  • the Fitzpatrick Company has a compaction division in Elmhurst, IL, which sells this type of equipment.
  • Another supplier of similar equipment is Alexanderwerk based in Germany and having a sales office in New Jersey.
  • the Chilsonator used two 4" long rolls having diameters of 1 0" . Vacuum was applied in the area of the vertical screw.
  • the material granulated was Carbopol ® 971 P, a lightly crosslinked polyacrylic acid powder.
  • SGF Simulated Gastric £luid (pH 1 .2)
  • SIF Simulated intestinal Fluid (pH6.8)
  • T 70 is time (in minutes) for 70% of the active ingredient (theophylline) to be released in SGF or SIF.
  • Tables I and la show that drug release time can be adjusted by manipulating roll compaction pressure.
  • the tablet from Table la release rate tests was formulated with a similar recipe to Table III, and compacted with sufficient pressure to result in a tablet with a hardness of 9-1 1 kilopounds using a standard U.S. P. crushing strength tester.
  • Tables I and lb show how thickening ability decreases only slightly with increasing compaction pressure. However, it should be noted that the gel surface may appear rougher with increasing com ⁇ paction pressure.
  • the following examples illustrate the physical characteristics of granules produced according to the present invention.
  • the samples were prepared using a Fitzpatrick IR-520 Chilsonator roll compactor and a M5A Fitzmill attritor.
  • Carbopol ® 971 P was used in the following examples.
  • Examples 1 and 2 utilize Carbopol granules from Table II above. Comparative examples include pow ⁇ dered polyacrylic acid and polyacrylic acid granules produced by fluid ⁇ ized bed granulation. All amounts used in % w/w.
  • Table IV shows properties of powder mixtures and tablets formed from granules prepared according to the present invention compared to powder mixtures and tablets formed from either powdered polyacrylic acid (Ex. 3) or granules produced via the fluidized bed technique (Ex. 4) .
  • T 70 and T 90 are time (in minutes) for 70% and 90% of active ingredient
  • SGF (pH 1 .2) Simulated Gastric Fluid
  • SIF(pH6.8) Simulated intestinal
  • Table IV shows that the flowability (flow-index) of the ta ⁇ bleting powder mixture prepared from various granular forms of poly ⁇ acrylic acid is not fundamentally related to the drug release perform ⁇ ance of the granules.
  • the compressibility index is 1 00 times the dif- ference between the tap density and bulk density divided by the tap density. In free flowing powders, the compressibility index is less than 1 5 % while values above 25% indicate poor flow characteristics.
  • Tables V-VII illustrate the dramatic effect of compression pressure during compaction of the polyacrylic acid granules on the properties of the tablet blends when using the polyacrylic acid as a 1 0 weight percent ingredient.
  • the polyacrylic acid of Example 5 was compacted under a pressure of 1 0 bar on an Alexanderwerk granulating machine, Example 6 was compacted under a pressure of 30 bar, and Example 7 was compacted under a pressure of 60 bar.
  • the tablet blends in Table V were formed in a 0.375-inch diameter die with a blend loading of 300 mg for each of Examples 5-7.
  • the force used for Examples 5 was 300 lbs, that for Example 6 was 364 lbs, and that for Examples 7 was 367 lbs.
  • the Hausner ratio is the tap density divided by the bulk density. It is to be noted that the hardness of the tablets from Examples 5-7 were 8.7, 8.8, and 8.4 lbs indicating that Examples 6 and 7 were not compressed into harder tablets than Example 5.
  • Table VI illustrates what a dramatic effect 1 0 weight percent of polyacrylic acid, granulated under different condi ⁇ tions, can have on the properties of blends used to make tablets and Table VII illustrates the dramatic effect on the release rate of theo ⁇ phylline.
  • theophyl ⁇ line is a very effective medication, but it can be toxic if released in concentrations above the pharmaceutically effective amounts.
  • There ⁇ fore uniform and controlled safe dosages of theophylline are critical in preparing effective tablets.
  • Table VI the blend before tablet making from the polyacrylic acid compacted under the lowest compaction pressure resulted in the densest blend with the highest compressibility (facilitating tablet formation at lower pressures) . When these blends were compressed into tablets the compaction pressures used to form granules of polyacrylic acid had little effect on the disintegration times.
  • the release time of theophylline by the tablets was dramatically decreased by increasing compaction roll pressure.

Abstract

The present invention pertains to a method for forming polyacrylic acid granules and granules formed therefrom wherein the granules are flowable, have an increased bulk density relative to the as polymerized polyacrylic acids, and a low amount of dust which is generally characterized herein as particles which pass through a 325 mesh screen. The granules formed by the method of the present invention can be used to prepare controlled release tablets, especially controlled release pharmaceutical tablets. The controlled release properties of the tablets formed from granules prepared according to the present invention are unexpectedly better than tablets prepared from granules formed by other known granulation methods.

Description

CONTROLLED RELEASE POLYACRYLIC ACID GRANULES AND
A PROCESS FOR PREPARING THE SAME
FIELD OF INVENTION
The present invention concerns a process for producing granulated polyacrylic acid. The polyacrylic polymers are highly swollen in aqueous media. The polyacrylic acid granules produced by the proc¬ ess of the present invention are useful in controlled release formulations (such as pharmaceutical tablets) . The powdered form of polyacrylic acid, which was previously used in controlled release applications, cre- ated material handling problems due to its poor powder flow character¬ istics, dust, and static charges associated with the dust.
BACKGROUND OF THE INVENTION
Many compounded solids originate or are manufactured as fine, light, and/or loose powders. Such powders often have poor flow characteristics and are resistant to blending and dispersion in liquids due to clumping and poor wetting. The dust associated with the powders can exhibit static charge effects. Additional problems include difficulty in handling and, difficulty in feeding through volumetric metering equipment. Many such powders have historically been granulated to vary their particle size distribution in order to improve their characteris¬ tics. In these applications the larger granules are a temporary state with the granules being easily broken back down into the smaller pow¬ der particles by shear or solvents in the final product. Polyacrylic acid resins, which are to be used in applications involving swelling with aqueous electrolyte solutions, are commonly polymerized in nonaqueous polymerizations where the insoluble polymer can be isolated as powders. These powders, comprised of aggregated or agglomerated polymer chains, are significantly easier to disperse and dissolve in water than the bulk polymer. However these polyacrylic acid powders have been noted for their static electricity charge, poor powder flow and some difficult in making dispersions in water since their introduction in 1 958.
While some of the difficulties in using and dispersing polyacrylic acids have been addressed by various improved polyacrylic acids e.g. US Patent 5,349,030 and by adding components to minimize the effects of ionic charges (e.g. counterions), the problems of product dusting and poor flowability continue to be significant issues, especially with the use of very pure polyacrylic acid resins used in the pharmaceutical industry. There are a variety of methods, which have been employed by powdered material suppliers and users in an attempt to reduce handling difficulties of powders. Slugging, hot roll milling, and fluidized bed or wet agglomeration processes are well known processes for converting powders to granules. Slugging compresses the powder into large tablets. Hot roll milling uses heat along with pressure to squeeze the powder into flakes or sheets. In either case, the compacted material is then reground into particles larger than the original powder grains. Both slugging and roll milling are relatively slow, low-capacity, energy- intensive processes. Roll milling has the additional disadvantages of re- quiring constant attention by a skilled operator.
Wet agglomeration techniques involve adding liquid to the original powder to increase the particle sizes and then drying the larger particles in trays or a fluidized bed. The resulting agglomerates can be used as is or ground to smaller sizes for specific uses. Dry granulation eliminates several problems inherent in conventional processes. Dry granulation of powder material is a two-step process, requiring no heating or wetting (depending on the starting ma¬ terial), in which the powder is first densified (compacted) into solid form, then broken into smaller particles and separated into predeter- mined sizes. To perform these steps, a granulation system combines several different kinds of specialized machines (usually in a vertical, gravity- assisted arrangement) to achieve a closed-loop operation. System components typically include: a feeding hopper, horizontal and vertical screws, compaction rollers, a prebreaker, a granulator, sizing/sorting screens, and a recycling elevator.
Granulated particles formed by the above processes are more easily handled than the powder from which they are formed. However, the granular particles may be too hard, too soft, too friable or not par- ticularly suitable, due to the particle size distribution, for their end use
(e.g. tablet forming processes).
Thus, there is a need to develop a process for preparing granulated polyacrylic acid suitable for controlled release applications e.g. pharmaceutical applications, from the polyacrylic acid powder. De- sirably the process would produce granules, which retain similar properties (attributes) during formulation, forming tablets, and releasing actives from tablets to the powder without the handling problems associated with the powder.
SUMMARY OF INVENTION
The present invention pertains to a method for forming polyacrylic acid granules and granules formed therefrom wherein the granules are flowable, have comparable swelling characteristics and provide comparable tablet properties to powdered polyacrylic acid, have increased bulk density, and contain minimal amounts of very small par¬ ticles that can cause dusting and/or static adherence. The granules from this process vary from other granules of similar materials in that they retain more of their dissolution and swelling characteristics in both aqueous solutions in slow release tablets than do prior art polyacrylic acid granules. The granules formed by the method of the present in¬ vention can be used to prepare controlled release tablets, especially controlled release pharmaceutical tablets where the granules have surprisingly similar characteristics during tablet formation with powders and form tablets with similar controlled release rates to tablets from the harder to handle powders. They can also be used as thickeners; emulsi- fiers and suspending agents in water based formulations based on other polar solvents.
Thus, a first advantage of the present invention is that polyacrylic acid powder is formulated into a granular product with better dry flow characteristics facilitating metering and mixing operations. An additional advantage is the production of a granular polyacrylic acid having better control over particle size, higher bulk density to minimize packaging, and lower static adherence compared to unprocessed powdered polyacrylic acid.
A further advantage is that the granular polyacrylic acid produced in accordance with the present invention has relatively low dusting compared to the powder form of polyacrylic acid.
A still further advantage of the granular polyacrylic acid of the present invention is that it results in the unexpectedly better controlled release of various active material from tablets formed from the granules than from tablets formed from granules produced by other granulation processes.
The term polyacrylic acid is used to include various homo- polymers and copolymers wherein at least 50 or 75 mole percent of the repeating units have pendant carboxylic acid groups or anhydrides of di- carboxylic acid groups. While acrylic acid is the most common primary monomer used to form polyacrylic acid the term is not limited thereto but includes generally all α-β unsaturated monomers with carboxylic pendant groups or anhydrides of dicarboxylic acids as described in U.S. 5,349,030. Other advantages and benefits of the invention will be¬ come apparent to those skilled in the art upon a reading and under- standing of the following detailed description of the preferred embodiments.
BRIEF DESCRIPTION OF THE DRAWINGS The Figure shows one example of a compaction/granulation system with a recycle mechanism.
DETAILED DESCRIPTION
In accordance with the practice of the present invention, a dry granulation apparatus A is provided as shown in the Figure. Variables such as the compaction pressure, roll speeds, attrition device and operation speed, and screening operations are used to control the particle densification and particle size distribution. These properties control the dissolution behavior of the polyacrylic acid when exposed to water or electrolyte solutions and its effectiveness as an additive in tablet formulations and controlled release applications.
Referring now to the Figure, the dry granulator A is provided with an original powder feed 1 0 which feeds powdered polyacrylic acid into a lower hopper 1 2. The powdered acrylic acid in lower hop- per 1 2 is then fed through feed channel 1 4 into an upper hopper 1 6.
The upper hopper 1 6 collects the virgin powdered polyacrylic acid and recycled powder which does not meet quality controlled sizing pa¬ rameters. The powdered acrylic acid in the upper hopper is then ini¬ tially fed into the granulation system via a horizontal feed screw 1 8. The rate of rotation of the horizontal feed screw 1 8 can be adjusted to permit continuous flow of the powdered polyacrylic acid into the granulation system without clogging. Next, a vertical screw 20 pre- compresses and deaerates the powered polyacrylic acid before feeding it into compaction rollers 22. Pressure is applied to compaction rollers 22 via a hydraulic actuator 24. The compaction rollers rotate in oppo¬ site directions so that powdered material fed from above will be pulled between the rollers, compressed and dropped into a prebreak mechanism 26 below. The prebreak mechanism 26 provides an initial breakup of the compressed polyacrylic acid into chips and flakes, which drop into attritor 28. The attritor 28 breaks up the compressed polyacrylic acid into desired particle sizes in conjunction with screen
30. Granulated polyacrylic acid falls into a screening system 32 wherein particles are separated via various sieves 34, the final product having the desired particle sizes being deposited into finished product hopper 36. The oversized and undersized particles 38 are processed via a recycle feed mechanism 40 back into feed channel 1 4, 42 to be reprocessed through the system.
Various powdered polyacrylic acids, or mixtures of polyacrylic acids, may be granulated according to the process of the present invention wherein the resulting granulated polyacrylic acid has en- hanced handling and performance properties compared to the powder.
The granulated polyacrylic acid prepared in accordance with the method described herein, when formulated into tablets retains an ability to slow down the release rate of an active material, compared to tablets formed from granules prepared by other known granulation processes. The granules also maintain more of their ability to thicken, emulsify, and suspend in water based formulations and formulations based on other polar solvents than prior art granules.
Polymeric powders which may be formed into granules that have improved handling, while retaining thickening and controlled release properties, include various acrylic acid homopolymers, copoly- mers, and interpolymers having a bulk density below about 0.3 g/cc. The term polyacrylic acid or acrylic acid polymers is used to encom¬ pass a variety of polymers having high percentages of polymerizable monomers therein with pendant carboxylic acid groups or anhydrides of polycarboxylic acid. These are described in more detail in U.S. Pat¬ ents 2,798,053; 3,91 5,921 ; 4,267, 1 03; 5,288,81 4; and 5,349,030 hereby incorporated by reference. The term polyacrylic acid is used to include various homopolymers, copolymers, and interpolymers, wherein at least 50 or 75 mole percent of the repeating units have pendant carboxylic acid groups or anhydrides of dicarboxylic acid groups. While acrylic acid is the most common primary monomer used to form polyacrylic acid the term is not limited thereto but includes generally all α-β unsaturated monomers with carboxylic pendant groups or anhydrides of dicarboxylic acids as described in U.S. 5,349,030. The term consisting essentially of anhydrous polyacrylic acid will be used to exclude more than 3 weight percent water and to exclude more than 0.2 mole percent multivalent metal cations based on the moles of carboxylic acid. Desirably, the amount of water is less than 1 or 2 weight percent. Desirably, the amount of multivalent metal cations is less than 0.1 mole percent and preferably less than 0.01 mole percent. In particular, the process according to the present inventions is useful for granulating various powdered polycarboxylic acids including cross-linked polyacrylic acids. Specific types of cross-linked polyacrylic acids include Carbopol® 971 P (polymerized in ethyl-acetate and partially neutralized with potassium); copolymers of acrylic acid and alkyl acrylates; copolymers of acrylic acid and alkyl vinyl ethers; copolymers of ethylene and maleic anhydride; and copolymers of maleic anhydride and alkyl vinyl ethers. An approved polyacrylic acid for pharmaceutical applications, described in a carbomer monograph in the U.S. Pharmocopia 23 NR 1 8, is a polyacrylic acid crosslinked with polyalkenyl ethers. The polymeric agents useable in the present in¬ vention are typically polymerized by precipitation polymerization in a non-aqueous medium and subsequently dried to strip off the solvent. The acrylic polymers typically have a flow index of above 30, appar¬ ently due to their low bulk density and electrostatic charge. The acrylic polymers of interest when dispersed in water and neutralized to a pH of 7 at a concentration of 1 0 g/L generally can im- part a viscosity of at least 500 centipoise and more desirably at least 2000 centipoise to the water solution as measured by a Brookfield viscometer using 20 rpm at 25 °C and selecting a spindle resulting in a torque reading between 1 0 and 90% of full scale. The improved handling properties of the granules prepared in accordance with the present invention are reflected by improvements over the powdered form of polyacrylic acid in areas such as powder flow rate, bulk density, percentage of fines (i.e. particles less than 325 U.S. Standard screen size), static adherence and total dust. The granulated product desirably retains the at least 70, 80 or 90% of the thickening capacity of the original fine powder when dispersed in water and neutralized to a pH of 7 at a concentration of 1 0 g/L. Thus the viscosity of such a solution is desirably at least 350, 400, or 450 centipoise and more desirably at least 1 400, 1 600 or 1 800 centipoise.
With respect to powder flow rate, the granules according to the present invention may have a flow index value of less than or equal to 25, desirably less than or equal to 20, and preferably less than or equal to 1 5. The flow index is measure by the Flodex™ equipment, which comprises a 35-45 mm diameter tube approximately 8-1 0 cm long. Bottom caps with incrementally larger diameter apertures are used in the apparatus until an aperture is found of sufficient diameter that the contents of the tube are substantially emptied from the tube when the aperture is unblocked by the operator. A flow index value is assigned equal to the diameter of the aperture used in mm through which the material flows easily. If the aperture is too small then bridging over occurs with a substantial amount of the tube contents being retained in the tube.
The bulk density of the granules is measured according to a typical bulk density method for powders. A 30-1 00 mL cup is used which can be lightly tapped one time after filling. The powder is dropped from a powder funnel which discharges about 4 to 8 cm above the rim of the cup. The excess material which accumulates above the rim of the cup can be removed by scraping with a spatula and the weight of the contents determined. The bulk density is the weight of the contents divided by their volume. A tap density can also be determined using a 1 00 mL graduated cylinder instead of a cup. The powder is discharged from the bottom of a powder funnel as set forth above. A tap density apparatus such as a J. Engelsmann A-G Tap Density Apparatus is used to tap the cylinder and contents 1 000 times. The volume and weight of the powder after tapping is recorded and the density is calculated as the weight divided by the volume.
Due to the propensity of very small particles to cause dusting, it is desirable to screen the granules to remove and recycle those granules which pass through a 325 U.S. Standard mesh screen. This is not to say that particles smaller than a 325 mesh screen are dust but rather that this size fraction includes more dust and/or carries more dust with it into other steps. Desirably the amount of granules that pass through said 325 mesh screen are less than 1 0 weight per- cent of the total granules, more desirably less than 5 weight percent, and preferably less than 2 weight percent of the granulated product after screening. The amount of granules passing through a 325 mesh screen can be determined by screening the granules until the weight of the material passing through the 325 mesh screen appears to be constant. If a screen analysis on the polyacrylic powder (before granulation) is desired, small sample sizes or air filtration techniques are recommended due to the substantial amount of very small parti¬ cles in the powder and static charge problems that occur during screening. Static charging for polyacrylic acid is generally visually de¬ termined. Powder samples in bags will exhibit a strong tendency for dust to adhere to the bag and any equipment and/or the operator. Samples of polyacrylic acid powder in glass and plastic jars (generally nonconductive) will exhibit large amounts of dust adhered by static electricity to the walls of the jar above the samples. Static charged dust particles will appear to exit the glass jar as a smoke due to static repulsion combined with Browman particle diffusion.
In order to achieve production of polyacrylic acid granules, which possess both the improved handling properties over the powder and retain acceptable tablet formation and controlled release proper- ties compared to the powder, a number of adjustable parameters must be controlled. These parameters include horizontal feed screw rate of rotation, vertical screw rotation speed, pressure applied to compaction rolls, speed of compaction rolls, attritor configuration and speed, and screen size. The speeds of the horizontal and vertical screws should be set to feed powder to the compaction rollers at a rate just fast enough to cause a slight separation (about 0.01 to about 0.2 or 0.5 inches, more desirably from about 0.02 to about 0.07 or 0.2 inch gap) between the rollers. Pressure is applied to the compaction rollers via the hydraulic actuator or other compaction device to produce a compacted mate¬ rial having a density of about 0.3 g/cc to about 1 .5 g/cc. Preferably, the density of the compacted material is from about 0.9 g/cc to about 1 .1 g/cc. These densities form strong enough aggregates and/or ag- glomerates that the amounts of undersized particles can be reduced without removing so much of the voids, cracks, and crevices (void volume) within the aggregates and agglomerates to prevent them uni¬ formly swelling in water or electrolyte solutions. The compaction rolls may have circumferiential corrugations, pocket indentations or corru- gations in the axial direction across the width of the roll . Applicants define the pressure via the result due to the complexity of specifying a compaction pressure applied from a curved surface to a powder.
Densification obviously is the result of compacting the aggregates and/or agglomerates (particles) present in the powder into larger particles. This reduces the void volume within the particles. It is believed that the void volume, to the extent that it is open to the surface of the particles, is a pathway for water or electrolyte solutions to enter each particle uniformly swelling the polyacrylic acid therein. Thus densification usually makes the interior of the particles less accessible to water or electrolyte solutions. Increased compaction also results in more interpolymer penetration between the surface polymers on aggregates and/or agglomerates, which can slow dissolution times of a particle due to the need for the interpenetrated polymers to separate and due to the possibility that the interpenetrated polymers may remain entangled and not be able to separate. It is to be noted that if the polyacrylic acid is over-densified then the resulting granules will only swell with water or electrolyte on their surfaces. This results in occlusions of nonswollen polymer (occluded polymer) within some or all granules.
The occluded (non-swellable) polyacrylic acid is not available to modify the viscosity of liquid solutions and is not available to control release rates in a tablet. Therefore there is an inverse relationship between the amount of occluded polyacrylic acid and the thickening and release controlling properties of the polyacrylic acid.
The compaction roller speed is set to maximize productivity without exceeding the horsepower limitation of the compaction equipment. Slower roller speeds allow the polyacrylic acid more time to flow and accommodate the stresses uniformly throughout the thickness of the compressed samples. Faster roller speeds may force the polyacrylic acid in direct contact with the roller surface to do most of the accommodation.
The speed and configuration of the attritor are chosen to provide optimal particle size distributions for a particular application. Smaller particles, such as those sized between the opening of a 1 00 and 200 mesh screen are desirable as they maximize the number of particles and total surface area. These properties are important, as smaller polyacrylic acid particles tend to form a tablet with better integrity and slower release rates for active material. Increases in the number of smaller particles decreases bulk density and decrease powder flow characteristics. It has also been observed that smaller particles form tablets with better tablet integrity in the dissolution tests. Larger particles, e.g. those sized between a 20 and 80 mesh screen, maximize bulk density and flow characteristics but contribute less to tablet formation and slow release rates. In most embodiments it is desirable to minimize generation of granules smaller than 325 mesh, more desirable less than 200 mesh (U .S. Standard) due to their con- tribution to dust.
Screen size is about 5 mesh to about 325 mesh (U.S. Standard); more desirably from about 20 to about 250, and preferably, screen size is from about 40 mesh to about 200 mesh. Thus, granules having a particle size of less than about 5 mesh (passing through 5 mesh) but greater than about 325 mesh (retained on 325 mesh) will be discharged as product. Particles which have sizes outside these parameters (oversized and undersized (fines)) will desirably be recycled back into the system if present in a significant amount.
Vacuum deaeration may be used to reduce air from becom- ing trapped in the powder prior to compaction. The vacuum may be adjusted to be from about 0.5 in. Hg. to about 30 in. Hg. Preferably 5 to 20. Desirably this vacuum is applied around the compaction rolls and optionally within the vertical and/or horizontal screw feeds. If al¬ ternative compaction or powder conveyance means are used they could include vacuum deaeration. Entrained air in the material from the initial compaction tends to expand uncontrollably as the com- pacted material comes out of the compaction rolls and fracture the compacted material.
The controlled release tablet formulations of the present invention include granulated polyacrylic acid prepared in accordance with the process of the invention. Amounts of polyacrylic acid used in tablet formulations are preferably from about 5 or 1 0% w/w to about 50 %w/w. The polyacrylic acid aids in tablet formation and tablet integrity. During controlled release applications the polyacrylic acid can swell which limits the porosity of the tablet (or application device) by restricting the flow of the electrolyte solution into and out of the tablet. Desirably the tablets made according to this disclosure have a release rate of from about 0.6 to about 24 hours or more for pharmaceutically active materials. Longer release rates are available for non-pharmaceutical applications where the longer release rates may be desirable.
Other conventional tableting adjuvants, including pharma¬ ceutically acceptable tableting adjuvants, can be included in the tablet formulations. Such adjuvants include fillers, excipients, compression aids, binders, flavorings, coating agents, etc. Various active materials, e.g. pharmaceuticals, may be for¬ mulated into the controlled release tablet formulations. Other active materials include biocides, disinfectants, stimulants, moisturizers, aromas, scents, chemicals (e.g. chlorine), proteins, etc which are beneficially applied from a table or gelled or thickened liquid formula- tion. Typically, pharmaceuticals dosages are designed to be adminis¬ tered in specific amounts over a broad time range to avoid toxicity problems, thus the need for controlled release formulations . Pharma¬ ceutical can include pain relievers, stimulants, muscle relaxants, anti¬ biotics, pain blockers, and a variety of other medications. Theophyl- line, for example, is one such agent, which is generally formulated in a controlled release tablet composition. Other pharmaceutical agents typically or desirably used in controlled release form are within the scope of acceptable pharmaceutical agents useable in the present invention's formulations.
Preparation Examples The following examples illustrate the processes for preparing polyacrylic acid granules, which possess the desired handling and controlled release properties.
Preparation Examples 1 and 2
The following examples utilized a Fitzpatrick Model 4L x 1 0D Chilsonator and DKAS01 2 FitzMill system. This equipment is illustrated in Figure 1 . The Fitzpatrick Company has a compaction division in Elmhurst, IL, which sells this type of equipment. Another supplier of similar equipment is Alexanderwerk based in Germany and having a sales office in New Jersey. The Chilsonator used two 4" long rolls having diameters of 1 0" . Vacuum was applied in the area of the vertical screw. The material granulated was Carbopol® 971 P, a lightly crosslinked polyacrylic acid powder.
Table
Figure imgf000016_0001
Table la
Figure imgf000017_0001
*SGF = Simulated Gastric £luid (pH 1 .2); SIF = Simulated intestinal Fluid (pH6.8); T70 is time (in minutes) for 70% of the active ingredient (theophylline) to be released in SGF or SIF.
Tables I and la show that drug release time can be adjusted by manipulating roll compaction pressure. The tablet from Table la release rate tests was formulated with a similar recipe to Table III, and compacted with sufficient pressure to result in a tablet with a hardness of 9-1 1 kilopounds using a standard U.S. P. crushing strength tester.
Table lb Viscosities of Aqueous Dispersions at Various Resin Concentrations (Neutralized to about pH7.5 with NaOH)
Figure imgf000017_0002
Viscosities measured with Brookfield viscometer, 20 rpm, 25 C using a spindle for which the total torque is 10 to 90% of full scale on the torque meter.
Tables I and lb show how thickening ability decreases only slightly with increasing compaction pressure. However, it should be noted that the gel surface may appear rougher with increasing com¬ paction pressure. Formulation Examples
The following examples illustrate the physical characteristics of granules produced according to the present invention. The samples were prepared using a Fitzpatrick IR-520 Chilsonator roll compactor and a M5A Fitzmill attritor. Carbopol®971 P was used in the following examples.
Table II
Figure imgf000018_0001
Smallest hole diameter (mm.) in Flodex™ through which material flows easily. Prepared by fluidized bed wet granulation with water.
The following Examples illustrate pharmaceutical tablet for¬ mulations comprising theophylline. Examples 1 and 2 utilize Carbopol granules from Table II above. Comparative examples include pow¬ dered polyacrylic acid and polyacrylic acid granules produced by fluid¬ ized bed granulation. All amounts used in % w/w.
Table III
Figure imgf000019_0001
*fluidized bed granulation.
Table IV, below, shows properties of powder mixtures and tablets formed from granules prepared according to the present invention compared to powder mixtures and tablets formed from either powdered polyacrylic acid (Ex. 3) or granules produced via the fluidized bed technique (Ex. 4) .
Table IV
Figure imgf000019_0002
granules produced by fluidized bed technique
T70 and T90 are time (in minutes) for 70% and 90% of active ingredient
(theophylline) to be released in SGF/SIF.
SGF (pH 1 .2) = Simulated Gastric Fluid; SIF(pH6.8) = Simulated intestinal
Fluid .
Table IV shows that the flowability (flow-index) of the ta¬ bleting powder mixture prepared from various granular forms of poly¬ acrylic acid is not fundamentally related to the drug release perform¬ ance of the granules. The compressibility index is 1 00 times the dif- ference between the tap density and bulk density divided by the tap density. In free flowing powders, the compressibility index is less than 1 5 % while values above 25% indicate poor flow characteristics.
The following Tables V-VII illustrate the dramatic effect of compression pressure during compaction of the polyacrylic acid granules on the properties of the tablet blends when using the polyacrylic acid as a 1 0 weight percent ingredient. The polyacrylic acid of Example 5 was compacted under a pressure of 1 0 bar on an Alexanderwerk granulating machine, Example 6 was compacted under a pressure of 30 bar, and Example 7 was compacted under a pressure of 60 bar.
Table V
Figure imgf000020_0001
Table VI
Properties of Tablet Blend
Figure imgf000020_0002
The tablet blends in Table V were formed in a 0.375-inch diameter die with a blend loading of 300 mg for each of Examples 5-7. The force used for Examples 5 was 300 lbs, that for Example 6 was 364 lbs, and that for Examples 7 was 367 lbs. These values were calculated based on the Hausner Ratio and the Compressibility Index of the tablet blend. The Hausner ratio is the tap density divided by the bulk density. It is to be noted that the hardness of the tablets from Examples 5-7 were 8.7, 8.8, and 8.4 lbs indicating that Examples 6 and 7 were not compressed into harder tablets than Example 5.
Table VII Properties of Tablet
Figure imgf000021_0001
The above Table VI illustrates what a dramatic effect 1 0 weight percent of polyacrylic acid, granulated under different condi¬ tions, can have on the properties of blends used to make tablets and Table VII illustrates the dramatic effect on the release rate of theo¬ phylline. As is well known to the pharmaceutical industry, theophyl¬ line is a very effective medication, but it can be toxic if released in concentrations above the pharmaceutically effective amounts. There¬ fore uniform and controlled safe dosages of theophylline are critical in preparing effective tablets. In Table VI the blend before tablet making from the polyacrylic acid compacted under the lowest compaction pressure resulted in the densest blend with the highest compressibility (facilitating tablet formation at lower pressures) . When these blends were compressed into tablets the compaction pressures used to form granules of polyacrylic acid had little effect on the disintegration times. The release time of theophylline by the tablets was dramatically decreased by increasing compaction roll pressure.
Results As can be seen from the tables above, granules produced in accordance with the present invention have enhanced flowability compared to the control powder (Table II) . Additionally, Table II shows the importance of screening out fines to achieve increased flowability. In addition to enhanced flowability, tablets prepared from granules of polyacrylic acid made in accordance with the process of the present invention possess enhanced (slowed down) controlled release properties over granules of polyacrylic acid prepared by other known granulation processes (i.e., fluidized bed) . While the controlled release properties of tablets prepared from granulated polyacrylic acid according to the present invention are not quite as slow as tablets prepared from powdered polyacrylic acid, the undesirable handling properties of prior art powders are avoided as the granules have im¬ proved flowability, lower static adherence and lower dust compared to the powdered polyacrylic acid itself. These major advantages in pre- tableting handling characteristics more than compensate for the somewhat lowered thickening efficiency or slight changes in the con¬ trolled release properties.
While in accordance with the patent statutes the best mode and preferred embodiment has been set forth, the scope of the inven¬ tion is not limited thereto, but rather by the scope of the attached

Claims

claims.WHAT IS CLAIMED IS:
1 . A process for granulating polyacrylic acid such that the granulated polyacrylic acid has the following properties:
(i) a flow index of <25, (ii) a bulk density of at least 0.35 g/cc, and (ii) less than 5 wt.% particles are fine enough to pass through a U.S. Standard 325 mesh screen, said process comprising:
(a) delivering a fine powder consisting essentially of anhydrous polyacrylic acid to a compaction device;
(b) compacting said polyacrylic acid into larger agglomerates and/or aggregates, (c) fracturing said agglomerates and/or aggregates into smaller granules;
(d) optionally screening said smaller granules to obtain the desired particle size range by removing or recycling in said process oversized and/or undersized granules, said polyacrylic acid being a polymer of one or more monomers characterized by having at least 50 mole percent repeating units having a carboxylic acid group and/or an anhydride of a dicarboxylic acid and when dispersed in water and neutralized to a pH of 7 at a concentration of 1 0 g/L imparting a viscosity of at least 500 centipoise to said water.
2. The process of claim 1 wherein said compacting of said poly¬ acrylic acid is achieved by the use of compaction rollers.
3. The method of claim 2 wherein said compacting rollers are adjusted to a separation between the roller of from about 0.01 to about 0.5 inches.
4. The method of claim 3, wherein the pressure on said rollers is sufficient to form a coherent strip from the compaction rollers.
5. The method of claim 1 wherein the polyacrylic acid is a cross linked polyacrylic acid.
6. The method of claim 1 wherein the fine powder, optionally with undersized and/or oversized granules, is delivered to said compaction device via one or more vertical and/or horizontal screws.
7. The method of claim 1 wherein the granules produced have an average particle size of between 5 and 325 U.S. Standard mesh screen.
8. A granular polyacrylic acid product produced by the process of claim 1 wherein the granular product has the following properties: (i) a flow index of <25,
(ii) a bulk density of at least 0.35 g/cc, (iii) less than 5 wt.% particles are fine enough to pass through a U.S. Standard 325 mesh screen, and,
(iv) said granular polyacrylic acid being a polymer of one or more monomers characterized by having at least 75 mole percent re¬ peating units having a carboxylic acid group or an anhydride of dicar¬ boxylic acid and when dispersed in water and neutralized to a pH of 7 at a concentration of 1 0 g/L imparting a viscosity of at least 400 centi¬ poise to said water.
9. A granular polyacrylic acid product according to claim 8 incorporated in a tablet.
1 0. A method for providing polyacrylic acid for controlled release applications including the steps of polymerizing acrylic acid with one or more other monomers in a nonaqueous media where the polyacrylic polymer is insoluble in the polymerization media and wherein the recovered polymer, when dispersed in water and neutralized to a pH of 7 at a concentration of 1 0 g/L, imparts a viscosity of at least 500 centipoise to the water, the improvement comprising;
(a) delivering a fine powder consisting essentially of anhydrous polyacrylic acid to a compaction device;
(b) compacting said polyacrylic acid into larger agglomer- ates and/or aggregates,
(c) fracturing said agglomerates and/or aggregates into smaller granules;
(d) optionally screening said smaller granules to obtain the desired particle size range by removing or recycling in said process oversized and/or undersized granules.
1 1 . The process of claim 1 0 wherein said compacting of said polyacrylic acid is achieved by the use of compaction rollers.
1 2. The method of claim 1 1 wherein said compacting rollers are adjusted to a separation between the roller of from about 0.01 to about 0.5 inches.
1 3. The method of claim 1 2, wherein the pressure on said rollers is sufficient to form a coherent strip from the compaction rollers.
14. The metnod of claim 1 0 wherein the polyacrylic acid is a cross linked polyacrylic acid.
1 5. The method of claim 10 wherein the fine powder, optionally with undersized granules, is delivered to said compaction device via one or more vertical and/or horizontal screws.
1 6. The method of claim 10 wherein the granules produced have an average particle size of between 5 and 325 U.S. Standard mesh screen.
1 7. In a method for making a controlled release tablet including the steps of
1 ) formulating a tablet blend from i) a material to be released in a con- trolled manner, ii) polyacrylic acid in a readily water swellable form, and iii) conventional tablet formation adjuvants, and
2) forming and compressing the tablet blend into a tablet, the improvement comprising a step prior to formulating said tablet blend of converting said polyacrylic acid in a readily water swellable form a fine powder to a granular form that is also readily water swellable by
(a) delivering a fine powder consisting essentially of anhydrous polyacrylic acid to a compaction device;
(b) compacting said polyacrylic acid into larger agglomerates and/or aggregates, (c) fracturing said agglomerates and/or aggregates into smaller granules;
(d) optionally screening said smaller granules to obtain the desired particle size range by removing or recycling in said process oversized and/or undersized granules, said polyacrylic acid being a polymer of one or more mono¬ mers characterized by having at least 50 mole percent repeating units having a carboxylic acid group and/or an anhydride of dicarboxylic acid and wherein said polyacrylic acid when dispersed in water and neutralized to a pH of 7 at a concentration of 1 0 g/L imparts a viscosity of at least 500 centipoise to said water.
PCT/US1999/016227 1998-08-02 1999-07-20 Controlled release polyacrylic acid granules and a process for preparing the same WO2000008092A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP99934124A EP1183302B1 (en) 1998-08-02 1999-07-20 Controlled release polyacrylic acid granules and a process for preparing the same
JP2000563720A JP4371394B2 (en) 1998-08-02 1999-07-20 Controlled release polyacrylic acid granules and process for their preparation
DE69929439T DE69929439T2 (en) 1998-08-02 1999-07-20 POLYACRYLIC ACID GRANULES WITH A TAX RELEASE AND METHOD FOR THE PRODUCTION THEREOF
BRPI9912846-2A BR9912846B1 (en) 1998-08-02 1999-07-20 process for manufacturing a controlled release tablet.
MXPA01000894A MXPA01000894A (en) 1998-08-02 1999-07-20 Controlled release polyacrylic acid granules and a process for preparing the same.
AU50024/99A AU5002499A (en) 1998-08-02 1999-07-20 Controlled release polyacrylic acid granules and a process for preparing the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9517998P 1998-08-02 1998-08-02
US09/329,471 1999-06-10
US09/329,471 US6492488B1 (en) 1998-08-02 1999-06-10 Controlled release polyacrylic acid granules and a process for preparing the same
US60/095,179 1999-06-10

Publications (1)

Publication Number Publication Date
WO2000008092A1 true WO2000008092A1 (en) 2000-02-17

Family

ID=26789936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/016227 WO2000008092A1 (en) 1998-08-02 1999-07-20 Controlled release polyacrylic acid granules and a process for preparing the same

Country Status (10)

Country Link
US (3) US6492488B1 (en)
EP (1) EP1183302B1 (en)
JP (1) JP4371394B2 (en)
CN (1) CN1197899C (en)
AT (1) ATE315605T1 (en)
AU (1) AU5002499A (en)
BR (1) BR9912846B1 (en)
DE (1) DE69929439T2 (en)
MX (1) MXPA01000894A (en)
WO (1) WO2000008092A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623754B2 (en) 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
WO2007022317A2 (en) * 2005-08-17 2007-02-22 Cadbury Adams Usa Llc Dusting compositions for chewing gum products
WO2009135951A2 (en) * 2008-05-09 2009-11-12 Atacama Labs Oy Process for preparing a tablet comprising metformin
WO2009135950A2 (en) * 2008-05-09 2009-11-12 Atacama Labs Oy Process for preparing a tablet containing excipients
WO2009135949A2 (en) * 2008-05-09 2009-11-12 Atacama Labs Oy Process for preparing a very high drug load tablet
EP2652123B1 (en) 2010-12-16 2016-01-13 Merck Patent GmbH Dry granulated cell culture media

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050126238A1 (en) * 2003-12-11 2005-06-16 Qc Corporation Plant nutrient and method of making
MX2007004135A (en) * 2004-10-04 2007-06-15 Oreal Cosmetic and/or dermatological composition for sensitive skins.
US20070048364A1 (en) * 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
US9224303B2 (en) 2006-01-13 2015-12-29 Silvertree Media, Llc Computer based system for training workers
FI20070521L (en) * 2006-11-10 2008-05-11 Atacama Labs Oy Grains, tablets and granulation process
US8951562B2 (en) 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
JP2009203419A (en) * 2008-02-29 2009-09-10 Lion Chemical Kk Sodium dichloroisocyanurate-containing tablet
EP2291233B1 (en) * 2008-05-09 2019-09-04 Atacama Labs Oy Method for dry granulation
IT1394597B1 (en) * 2008-11-05 2012-07-05 Politi DRY GRANULATION IN GAS FLOW.
JP5718817B2 (en) * 2009-09-16 2015-05-13 株式会社日本触媒 Method for producing water absorbent resin powder
EP2701532B1 (en) 2011-04-29 2017-11-15 Intercontinental Great Brands LLC Encapsulated acid, method for the preparation thereof, and chewing gum comprising same
CN103147325A (en) * 2013-03-19 2013-06-12 太仓市佳玲塑料制品有限公司 Preparation technology of colored polyacrylic acid particles
CN106422975B (en) * 2016-09-22 2023-03-21 张家港汇普光学材料有限公司 Automatic granulation equipment for zinc sulfide used in optical infrared imaging
CN111497169A (en) * 2020-04-21 2020-08-07 广东技塑新材料股份有限公司 Automatic conveying system for recycling defective granules in online plastic granulation
US11904425B2 (en) * 2022-05-09 2024-02-20 Compass Systems & Sales, LLC Method and apparatus for separating waste material

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122544A (en) * 1988-05-31 1992-06-16 Nalco Chemical Company Process for producing improved superabsorbent polymer aggregates from fines
WO1993023457A1 (en) * 1992-05-09 1993-11-25 Gel-Chem Limited Conversion of powdered polymers
DE19600324A1 (en) * 1996-01-08 1997-07-10 Basf Ag Granules for cosmetic and pharmaceutical preparations
RU2084462C1 (en) * 1994-04-12 1997-07-20 Саратовский филиал Научно-исследовательского института химии и технологии полимеров им.акад.В.А.Каргина Process for preparing powdery acrylic copolymers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
CH606154A5 (en) 1974-07-02 1978-11-15 Goodrich Co B F
US4267103A (en) 1978-12-07 1981-05-12 The B. F. Goodrich Company Solvent polymerization of carboxyl containing monomers
US4386120A (en) * 1980-01-07 1983-05-31 Nippon Kayaku Kabushiki Kaisha Process for producing polyacrylic acid salt granules easily soluble in water
HU190619B (en) * 1983-11-11 1986-09-29 Bezzegh,Denes,Hu Process for producing tablets with controlled dissolution of active ingredients
US4654039A (en) * 1985-06-18 1987-03-31 The Proctor & Gamble Company Hydrogel-forming polymer compositions for use in absorbent structures
ATE119766T1 (en) * 1989-10-26 1995-04-15 Nippon Shinyaku Co Ltd PREPARATION FOR THE STOMACH.
GB9114095D0 (en) 1991-06-29 1991-08-14 Allstate Limited Improvements in water-soluble polymers
US5288814A (en) 1992-08-26 1994-02-22 The B. F. Goodrich Company Easy to disperse polycarboxylic acid thickeners

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122544A (en) * 1988-05-31 1992-06-16 Nalco Chemical Company Process for producing improved superabsorbent polymer aggregates from fines
WO1993023457A1 (en) * 1992-05-09 1993-11-25 Gel-Chem Limited Conversion of powdered polymers
RU2084462C1 (en) * 1994-04-12 1997-07-20 Саратовский филиал Научно-исследовательского института химии и технологии полимеров им.акад.В.А.Каргина Process for preparing powdery acrylic copolymers
DE19600324A1 (en) * 1996-01-08 1997-07-10 Basf Ag Granules for cosmetic and pharmaceutical preparations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199810, Derwent World Patents Index; Class A14, AN 1998-109008, XP002125662 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623754B2 (en) 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
WO2007022317A2 (en) * 2005-08-17 2007-02-22 Cadbury Adams Usa Llc Dusting compositions for chewing gum products
WO2007022317A3 (en) * 2005-08-17 2007-10-11 Cadbury Adams Usa Llc Dusting compositions for chewing gum products
WO2009135951A2 (en) * 2008-05-09 2009-11-12 Atacama Labs Oy Process for preparing a tablet comprising metformin
WO2009135950A2 (en) * 2008-05-09 2009-11-12 Atacama Labs Oy Process for preparing a tablet containing excipients
WO2009135949A2 (en) * 2008-05-09 2009-11-12 Atacama Labs Oy Process for preparing a very high drug load tablet
WO2009135951A3 (en) * 2008-05-09 2010-10-28 Atacama Labs Oy Process for preparing a tablet comprising metformin
WO2009135949A3 (en) * 2008-05-09 2010-10-28 Atacama Labs Oy Process for preparing a very high drug load tablet
WO2009135950A3 (en) * 2008-05-09 2010-10-28 Atacama Labs Oy Process for preparing a tablet containing excipients
EP2652123B1 (en) 2010-12-16 2016-01-13 Merck Patent GmbH Dry granulated cell culture media

Also Published As

Publication number Publication date
CN1357023A (en) 2002-07-03
DE69929439T2 (en) 2006-09-21
US20020086967A1 (en) 2002-07-04
JP4371394B2 (en) 2009-11-25
CN1197899C (en) 2005-04-20
US6596844B2 (en) 2003-07-22
US6492488B1 (en) 2002-12-10
ATE315605T1 (en) 2006-02-15
MXPA01000894A (en) 2002-06-04
BR9912846A (en) 2002-07-09
EP1183302B1 (en) 2006-01-11
BR9912846B1 (en) 2009-12-01
EP1183302A1 (en) 2002-03-06
US20030187167A1 (en) 2003-10-02
AU5002499A (en) 2000-02-28
JP2002537410A (en) 2002-11-05
DE69929439D1 (en) 2006-04-06
US6762267B2 (en) 2004-07-13

Similar Documents

Publication Publication Date Title
US6762267B2 (en) Controlled release polyacrylic acid granules and a process for preparing the same
US6623754B2 (en) Dosage form of N-acetyl cysteine
US5171781A (en) Polymeric compositions
US6623756B1 (en) Directly compressed solid dosage articles
CA1339850C (en) Polymeric compositions
JP5612462B2 (en) Particulate material for dosage forms
GB1603533A (en) Excipients and their use
JP2002537410A5 (en)
US4405486A (en) Method for preparing granulated perborate salts containing a polymeric fluorocarbon
EP0277017A2 (en) Coal compositions and their production
USRE19750E (en) Manufacture of products of carbon
US5554707A (en) Granular vinyl chloride resin and process for its preparation
JP2940092B2 (en) Method for producing granular vinyl chloride resin
JPH04272933A (en) Maleic anhydride-methyl vinyl ether copolymer having increased bulk density
EP0102419A1 (en) A granulated perborate salt product, and process for producing the same
JP3203726B2 (en) Vinyl chloride resin for granular paste
EP2922907A1 (en) Process for preparing a granulated product from a powder composition
JPH0840973A (en) Sodium monochloroacetate with improved usability
Nikolovska et al. Roller compaction technology

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99811880.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1999934124

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 563720

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000894

Country of ref document: MX

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 1999934124

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1999934124

Country of ref document: EP